Form 4: Dynavax Technologies Corp Executive Novack David F Reports Stock Transactions

David F. Novack, President & COO of Dynavax Technologies Corp, reports the sale and acquisition of common stock and stock options on March 24, 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On March 24, 2025, David F. Novack, President & COO of Dynavax Technologies Corp, engaged in transactions involving the company's stock.
• Novack exercised a stock option to acquire 10,000 shares of common stock at a price of $6.805 per share.
• Simultaneously, Novack sold 10,000 shares of common stock at $14.00 per share.
• Following these transactions, Novack directly owns 8,078 shares of Dynavax common stock and holds options for 186,528 shares.
• The stock sales were executed under a 10b5-1 trading plan adopted on December 6, 2024.
• The option grant vests over three years, starting December 16, 2019.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports transactions executed under a pre-existing plan. There's no inherent positive or negative signal.

Positives

• The reporting person still holds a significant number of shares and options, indicating continued alignment with the company's success.

Negatives

• The sale of shares by an executive could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create uncertainty in the market.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The vesting schedule of the options (three years) is typical for such grants.
• The use of a 10b5-1 trading plan is a common practice among executives to manage their stock sales in a transparent and compliant manner.
• Comparable companies such as Moderna, BioNTech, and Novavax also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on how they interpret the executive's stock sale.

Key Dates

Keywords

Dynavax, DVAX, Novack, Stock Options, Form 4, Executive, Share Sale, 10b5-1 Trading Plan, Beneficial Ownership